Heart failure reviewsHumansCardiomyopathyHypertrophicDouble-Blind MethodEchocardiography
Evaluating the role of mavacamten in symptomatic non-obstructive hypertrophic cardiomyopathy: the ODYSSEY-HCM trial.
Kaveh Hosseini, Sina Kazemian, Sivadasanpillai Harikrishnan, Aaron L Sverdlov, Baljash S Cheema, Zahra Hassan Abdulla Juma, Tor Biering-Sørensen, Avishay Grupper
Published: 202510.1007/s10741-025-10578-z
Abstract
Non-obstructive hypertrophic cardiomyopathy (nHCM) is defined by exertional limitation without left ventricular outflow tract obstruction and lacks approved targeted therapies. ODYSSEY-HCM was a phase 3, randomized, double-blind, placebo-controlled t…
Preview only. Read the full abstract at the source